Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced ALK+ non-small cell lung cancer (NSCLC).

Authors

Vera Hirsh

McGill University Health Centre, Montreal, QC, Canada

Vera Hirsh , Fiona Helen Blackhall , Dong-Wan Kim , Benjamin Besse , Hiroshi Nokihara , Ji-Youn Han , Vanessa Roberts Tassell , Arlene Reisman , Shrividya Iyer , Alice Tsang Shaw

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)

First Author: Tony Mok

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC).

First Author: Benjamin J. Solomon

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).

First Author: Dong-Wan Kim

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Management of patients with ALK-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial.

First Author: Todd Michael Bauer